Discontinue use if progressive multifocal leukoencephalopathy is confirmed; serious opportunistic or recurrent infections develops in patients w/ low Ig; prolonged hypogammaglobulinemia requiring treatment w/ IV Ig. Not to be inj into moles, scars, stretch marks, tender, bruised, red, scaly or hard skin. Increased risk of infection; HBV reactivation & infection; inj-related reactions. Perform HBV screening including HBsAg, hepatitis B core Ab & quantitative serum Ig prior to therapy. Immunogenicity. Not recommended w/ live or live-attenuated vaccines. Concomitant use w/ immunosuppressive therapy. Women of childbearing potential should use effective contraception during & at least 6 mth after last dose. Pregnancy & lactation. Childn.